FDA Approves Weight Loss Drug Wegovy for Reducing Heart Attack, Stroke Risks

Wegovy is now approved in the U.S. as the first therapy to help people manage their weight and reduce cardiovascular risk.

A packaging for Novo Nordisk's Wegovy medication. Novo Nordisk via AP

The U.S. Food and Drug Administration (FDA) approved on Friday the first weight-loss drug for use to reduce the risks of life-threatening cardiovascular events in overweight or obese adults.

Drugmaker Novo Nordisk said that it received FDA approval to update the labeling of its weight loss drug Wegovy stating that it can be used to reduce a patient’s risk of heart attack, stroke, and cardiovascular death.